The FDA recently granted 510(k) clearance to Avenda Health, a Rosenman Innovator company, for its prostate cancer mapping platform. Using a patient’s diagnostic data, the platform defines the extent of one’s cancer, advancing the standard for prostate cancer care.
Read the full story here.
